<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39425479</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1875-9114</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Pharmacotherapy</Title><ISOAbbreviation>Pharmacotherapy</ISOAbbreviation></Journal><ArticleTitle>Use of proton pump inhibitors and risk of severe COVID-19: A case-control study in United States Medicare beneficiaries.</ArticleTitle><Pagination><StartPage>803</StartPage><EndPage>810</EndPage><MedlinePgn>803-810</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/phar.4614</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Concerns have been raised regarding proton pump inhibitor (PPI) use and risk of severe coronavirus disease 2019 (COVID-19). Observational studies have yielded heterogeneous results and were subject to important methodological limitations.</AbstractText><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To examine the association between the receipt of PPIs and risk of COVID-19 hospitalizations and severe in-hospital outcomes or death.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Case-control study among Medicare fee-for-service beneficiaries 66+ years old with gastroesophageal reflux disorder (GERD). Within this population, we identified cases by an incident hospital discharge diagnosis of COVID-19 from April 1 to December 11, 2020, using the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) U07.1, and randomly selected up to 10 controls per case, matched on date and neighborhood. We defined PPI use as a prescription providing ≥15 days of supply in the 30 days before admission, with H2-receptor antagonist (H2RA) use as the reference to account for indication. We analyzed uncomplicated hospitalizations and hospitalizations with severe outcomes (intensive/coronary care unit admission, invasive mechanical ventilation, or death), estimating odds ratios (ORs), and 95% confidence intervals (CIs) with multinomial conditional logistic regression adjusted for demographics, comorbidities, chronic medications, and health care utilization.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We matched 25,867 uncomplicated and 12,954 severe hospitalized COVID-19 cases to 146,972 and 73,104 controls, respectively. Cases tended to be older and have more comorbidities. Relative to H2RA use, we found no association of PPI use with uncomplicated COVID-19 hospitalization (OR 0.99, 95% CI 0.93-1.06) or severe COVID-19 hospitalization (OR 1.00, 95% CI 0.91-1.10).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Relative to H2RA use, PPI use was not associated with uncomplicated or severe COVID-19 hospitalizations among Medicare beneficiaries with GERD.</AbstractText><CopyrightInformation>Published 2024. This article is a U.S. Government work and is in the public domain in the USA.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mosholder</LastName><ForeName>Andrew D</ForeName><Initials>AD</Initials><AffiliationInfo><Affiliation>Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Izurieta</LastName><ForeName>Hector S</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Rongmei</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shangguan</LastName><ForeName>Shanlai</ForeName><Initials>S</Initials><Identifier Source="ORCID">0009-0002-6530-9407</Identifier><AffiliationInfo><Affiliation>Acumen, LLC, Burlingame, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akhtar</LastName><ForeName>Sandia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Acumen, LLC, Burlingame, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wernecke</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Acumen, LLC, Burlingame, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Jiwei</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chillarige</LastName><ForeName>Yoganand</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Acumen, LLC, Burlingame, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feng</LastName><ForeName>Yuhui</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Acumen, LLC, Burlingame, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avagyan</LastName><ForeName>Armen</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Acumen, LLC, Burlingame, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leishear</LastName><ForeName>Kira</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forshee</LastName><ForeName>Richard A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>MaCurdy</LastName><ForeName>Thomas E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Acumen, LLC, Burlingame, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Economics, Stanford University, Palo Alto, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelman</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Centers for Medicare and Medicaid Services, Washington, DC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graham</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>This study was funded in full by the U.S. Food and Drug Administration, through an interagency agreement with the Centers for Medicare &amp; Medicaid Services. There were no extra-institutional sources of funding.</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pharmacotherapy</MedlineTA><NlmUniqueID>8111305</NlmUniqueID><ISSNLinking>0277-0008</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054328">Proton Pump Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006635">Histamine H2 Antagonists</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054328" MajorTopicYN="Y">Proton Pump Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006278" MajorTopicYN="Y">Medicare</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="Y">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005764" MajorTopicYN="Y">Gastroesophageal Reflux</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006635" MajorTopicYN="N">Histamine H2 Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID‐19</Keyword><Keyword MajorTopicYN="N">GERD</Keyword><Keyword MajorTopicYN="N">H2RA</Keyword><Keyword MajorTopicYN="N">PPI</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>12</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>19</Day><Hour>16</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>19</Day><Hour>1</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39425479</ArticleId><ArticleId IdType="doi">10.1002/phar.4614</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565‐574.</Citation></Reference><Reference><Citation>Johns Hopkins Coronavirus Resource Center. Accessed March 30 2023. https://coronavirus.jhu.edu/us‐map.</Citation></Reference><Reference><Citation>Delshad SD, Almario CV, Chey WD, Spiegel BM. Prevalence of gastroesophageal reflux disease and proton pump inhibitor‐refractory symptoms. Gastroenterology. 2020;158(5):1250‐1261.</Citation></Reference><Reference><Citation>Ray A, Sharma S, Sadasivam B. The potential therapeutic role of proton pump inhibitors in COVID‐19: hypotheses based on existing evidences. Drug Res. 2020;70(10):484‐488.</Citation></Reference><Reference><Citation>Ramachandran P, Perisetti A, Gajendran M, et al. Pre‐hospitalization proton pump inhibitor use and clinical outcomes in COVID‐19. Eur J Gastroenterol Hepatol. 2022;34(2):137‐141.</Citation></Reference><Reference><Citation>Pranata R, Huang I, Lawrensia S, et al. Proton pump inhibitor on susceptibility to COVID‐19 and its severity: a systematic review and meta‐analysis. Pharmacol Rep. 2021;73(6):1642‐1649.</Citation></Reference><Reference><Citation>Kim HB, Kim JH, Wolf BJ. Acid suppressant use in association with incidence and severe outcomes of COVID‐19: a systematic review and meta‐analysis. Eur J Clin Pharmacol. 2022;1:1‐9.</Citation></Reference><Reference><Citation>Griffith GJ, Morris TT, Tudball MJ, et al. Collider bias undermines our understanding of COVID‐19 disease risk and severity. Nat Commun. 2020;11(1):5749.</Citation></Reference><Reference><Citation>Etminan M, Nazemipour M, Mansournia MA. Potential biases in studies of acid‐suppressing drugs and COVID‐19 infection. Gastroenterology. 2021;160(5):1443‐1446.</Citation></Reference><Reference><Citation>Freedberg DE, Conigliaro J, Wang TC, et al. Famotidine use is associated with improved clinical outcomes in hospitalized COVID‐19 patients: a propensity score matched retrospective cohort study. Gastroenterology. 2020;159(3):1129‐1131.</Citation></Reference><Reference><Citation>Chowdhury ATMM, Kamal A, Abbas MK, et al. Role of H 2 receptor blocker famotidine over the clinical recovery of COVID‐19 patients: a randomized controlled trial. World J Clin Cases. 2022;10(23):8170‐8185.</Citation></Reference><Reference><Citation>Samimagham HR, Hassani Azad M, Arabi M, et al. The efficacy of famotidine in improvement of outcomes in hospitalized COVID‐19 patients: a phase III randomized clinical trial. J Res Appl Basic Med Sci. 2022;8(2):75‐82.</Citation></Reference><Reference><Citation>Brennan CM, Nadella S, Zhao X, et al. Oral famotidine versus placebo in non‐hospitalised patients with COVID‐19: a randomised, double‐blind, data‐intense, phase 2 clinical trial. Gut. 2022;71(5):879‐888.</Citation></Reference><Reference><Citation>Cheema HA, Shafiee A, Athar MM, et al. No evidence of clinical efficacy of famotidine for the treatment of COVID‐19: a systematic review and meta‐analysis. J Infect. 2023;86(2):154‐225.</Citation></Reference><Reference><Citation>Kadri SS, Gundrum J, Warner S, et al. Uptake and accuracy of the diagnosis code for COVID‐19 among US hospitalizations. JAMA. 2020;324(24):2553‐2554.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. ICD‐10‐CM Official Coding Guidelines—Supplement Coding encounters related to COVID‐19 Coronavirus Outbreak Effective: February 20, 2020. 2020 Accessed August 2 2024. https://www.cdc.gov/nchs/data/icd/ICD‐10‐CM‐Official‐Coding‐Gudance‐Interim‐Advice‐coronavirus‐feb‐20‐2020.pdf</Citation></Reference><Reference><Citation>Agresti A. Categorical Data Analysis. 2nd ed. John Wiley &amp; Sons, Inc.; 2002:272‐274.</Citation></Reference><Reference><Citation>Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity‐score matched samples. Stat Med. 2009;28:3083‐3310.</Citation></Reference><Reference><Citation>Segal JB, Chang HY, Du Y, Walston JD, Carlson MC, Varadhan R. Development of a claims‐based frailty indicator anchored to a well‐established frailty phenotype. Med Care. 2017;55(7):716‐722.</Citation></Reference><Reference><Citation>Fackler WK, Ours TM, Vaezi MF, Richter JE. Long‐term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology. 2002;122(3):625‐632.</Citation></Reference><Reference><Citation>Almario CV, Chey WD, Spiegel BMR. Increased risk of COVID‐19 among users of proton pump inhibitors. Am J Gastroenterol. 2020;115(10):1707‐1715.</Citation></Reference><Reference><Citation>Luxenburger H, Sturm L, Biever P, et al. Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID‐19: coincidence or underestimated risk factor? J Intern Med. 2021;289(1):121‐124.</Citation></Reference><Reference><Citation>Holmberg MJ, Andersen LW. Collider bias. JAMA. 2022;327(13):1282‐1283. doi:10.1001/jama.2022.1820</Citation></Reference><Reference><Citation>Lee SW, Ha EK, Yeniova AÖ, et al. Severe clinical outcomes of COVID‐19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching. Gut. 2021;70:76‐84.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>